A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations
INTRODUCTION: Vildagliptin, a dipeptidyl peptidase-4 inhibitor, is indicated to cure type 2 diabetes mellitus (T2DM). This systematic literature search aims to assess the current knowledge about the clinical pharmacokinetics (PK) of vildagliptin to provide recommendations for clinical use to prevent the harmful effects of this drug.
METHODS: The PubMed, Science Direct, EBSCO, Cochrane Central Register of Controlled Trials, and Google Scholar databases were screened for articles related to the clinical PK of vildagliptin using systematic search strategies.
RESULTS: The literature search identified 2118 records, among which 28 were subsumed in this systematic review that fulfilled the inclusion standards.
CONCLUSIONS: This systematic review can help dose optimization among critically ill patients (e.g. renal impairment) without exposing them to the drug's toxic effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Expert opinion on drug metabolism & toxicology - 19(2023), 12 vom: 27. Dez., Seite 991-1003 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pasha, Mahnoor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dipeptidyl-Peptidase IV Inhibitors |
|---|
| Anmerkungen: |
Date Completed 25.01.2024 Date Revised 25.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425255.2023.2288252 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365001597 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365001597 | ||
| 003 | DE-627 | ||
| 005 | 20240126232021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425255.2023.2288252 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM365001597 | ||
| 035 | |a (NLM)38008954 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pasha, Mahnoor |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2024 | ||
| 500 | |a Date Revised 25.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Vildagliptin, a dipeptidyl peptidase-4 inhibitor, is indicated to cure type 2 diabetes mellitus (T2DM). This systematic literature search aims to assess the current knowledge about the clinical pharmacokinetics (PK) of vildagliptin to provide recommendations for clinical use to prevent the harmful effects of this drug | ||
| 520 | |a METHODS: The PubMed, Science Direct, EBSCO, Cochrane Central Register of Controlled Trials, and Google Scholar databases were screened for articles related to the clinical PK of vildagliptin using systematic search strategies | ||
| 520 | |a RESULTS: The literature search identified 2118 records, among which 28 were subsumed in this systematic review that fulfilled the inclusion standards | ||
| 520 | |a CONCLUSIONS: This systematic review can help dose optimization among critically ill patients (e.g. renal impairment) without exposing them to the drug's toxic effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 4 | |a peak plasma concentration | |
| 650 | 4 | |a renal impairment | |
| 650 | 4 | |a systematic review | |
| 650 | 4 | |a vildagliptin | |
| 650 | 7 | |a Dipeptidyl-Peptidase IV Inhibitors |2 NLM | |
| 650 | 7 | |a Vildagliptin |2 NLM | |
| 650 | 7 | |a I6B4B2U96P |2 NLM | |
| 700 | 1 | |a Zamir, Ammara |e verfasserin |4 aut | |
| 700 | 1 | |a Ashraf, Waseem |e verfasserin |4 aut | |
| 700 | 1 | |a Imran, Imran |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Rehman, Anees Ur |e verfasserin |4 aut | |
| 700 | 1 | |a Aziz, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Faleh |e verfasserin |4 aut | |
| 700 | 1 | |a Rasool, Muhammad Fawad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug metabolism & toxicology |d 2005 |g 19(2023), 12 vom: 27. Dez., Seite 991-1003 |w (DE-627)NLM164308237 |x 1744-7607 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:12 |g day:27 |g month:12 |g pages:991-1003 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425255.2023.2288252 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 12 |b 27 |c 12 |h 991-1003 | ||